Hospital
Genesis Healthcare System
Genesis Healthcare System was paid $101.92M by Medicaid between Jan 2018 and Dec 2024, across 633 billing codes. Its largest line is 99283, emergency room visit (moderate) — 12% of everything it billed.
33Billing provider infoGENESIS HEALTHCARE SYSTEM
ZANESVILLE, OH 43701
ZANESVILLE, OH 43701
33aNPI1598868655assigned 09/06/2006
33bProvider typeRural Acute Care Hospital
28Total paid$101.92M
24GClaims2,832,746
24DCodes billed633
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 237,169 | $6.63M | |
| 2019 | 249,788 | $7.13M | |
| 2020 | 219,395 | $10.17M | |
| 2021 | 265,212 | $11.31M | |
| 2022 | 286,146 | $10.43M | |
| 2023 | 866,947 | $29.81M | |
| 2024incomplete | 708,089 | $26.44M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 106,183 | 99,411 | $12.01M |
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 38,821 | 32,103 | $11.09M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.3% | 53,110 | 48,901 | $6.39M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 4.6% | 53,198 | 48,272 | $4.71M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.5% | 37,358 | 32,224 | $4.57M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.3% | 23,681 | 22,421 | $4.39M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.2% | 29,614 | 28,638 | $3.25M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.9% | 13,117 | 11,663 | $2.99M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.4% | 33,041 | 9,900 | $2.43M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.3% | 24,434 | 21,017 | $2.34M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 8,271 | 7,323 | $1.67M |
| J9271 | Injection, pembrolizumab, 1 mg | 1.4% | 187 | 150 | $1.45M |
621 more codes
| G0378 | Hospital observation service, per hour | 1.3% | 20,839 | $1.37M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.3% | 2,519 | $1.37M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 5,054 | $1.36M |
| 59025 | Fetal non-stress test | 1.2% | 8,007 | $1.24M |
| 80053 | Comprehensive metabolic panel | 1.2% | 90,637 | $1.21M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 10,483 | $1.06M |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 34,875 | $994K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,599 | $956K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,115 | $871K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 19,546 | $841K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 42,475 | $837K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 8,418 | $827K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 2,502 | $811K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,919 | $791K |
| 95811 | <1% | 1,641 | $778K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,407 | $764K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,777 | $694K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 89,904 | $614K |
| 80061 | Lipid panel | <1% | 38,289 | $555K |
| 95886 | <1% | 2,319 | $543K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,471 | $540K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 19,540 | $505K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 877 | $484K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 6,866 | $470K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,764 | $466K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 14,330 | $452K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 156,297 | $443K |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 2,817 | $416K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,060 | $365K |
| 97533 | <1% | 4,868 | $364K | |
| 62323 | <1% | 935 | $361K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 21,024 | $355K |
| 93458 | <1% | 434 | $342K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 892 | $341K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 13,730 | $327K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 14,230 | $306K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 662 | $291K |
| 36475 | <1% | 170 | $289K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,456 | $289K |
| 47563 | <1% | 122 | $278K | |
| 30802 | <1% | 152 | $266K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 28,419 | $260K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,061 | $259K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,293 | $251K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 6,288 | $251K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 470 | $248K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 11,938 | $241K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 465 | $237K |
| 36415 | Collection of venous blood by venipuncture | <1% | 204,157 | $234K |
| 85027 | <1% | 27,753 | $232K | |
| 93971 | <1% | 2,846 | $227K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 10,282 | $226K |
| 70496 | <1% | 857 | $226K | |
| 94060 | <1% | 2,039 | $219K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 275 | $216K |
| 84439 | <1% | 15,911 | $210K | |
| 97161 | <1% | 2,988 | $207K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 24,632 | $205K |
| 96415 | <1% | 864 | $200K | |
| 93308 | <1% | 840 | $197K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 888 | $193K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,986 | $192K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 810 | $192K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,135 | $190K |
| 71250 | <1% | 1,979 | $189K | |
| 93350 | <1% | 801 | $185K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 16,551 | $179K |
| 82607 | <1% | 8,525 | $179K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,025 | $178K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 942 | $176K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,501 | $172K |
| 93970 | <1% | 1,271 | $162K | |
| 73630 | <1% | 5,113 | $154K | |
| 84484 | <1% | 40,837 | $154K | |
| 76642 | <1% | 1,440 | $145K | |
| 74178 | <1% | 621 | $144K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 21,997 | $140K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,586 | $138K |
| 71271 | <1% | 762 | $135K | |
| 83655 | <1% | 5,079 | $133K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 3,681 | $132K |
| J0897 | Injection, denosumab, 1 mg | <1% | 159 | $131K |
| 76536 | <1% | 1,307 | $130K | |
| 93017 | <1% | 1,991 | $128K | |
| 97162 | <1% | 2,013 | $127K | |
| 70491 | <1% | 476 | $126K | |
| J3490 | Unclassified drugs | <1% | 85,639 | $121K |
| 12001 | <1% | 806 | $120K | |
| 95816 | <1% | 919 | $117K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 965 | $112K |
| 96367 | <1% | 2,593 | $111K | |
| 97597 | <1% | 1,816 | $107K | |
| 72141 | <1% | 659 | $106K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 11,876 | $105K |
| 94729 | <1% | 2,114 | $101K | |
| 73221 | <1% | 523 | $100K | |
| 76775 | <1% | 1,141 | $97K | |
| 93270 | <1% | 1,300 | $95K | |
| 94726 | <1% | 1,863 | $94K | |
| 84481 | <1% | 5,955 | $93K | |
| 74018 | <1% | 2,268 | $93K | |
| 36430 | <1% | 474 | $92K | |
| J9299 | Injection, nivolumab, 1 mg | <1% | 35 | $91K |
| 93976 | <1% | 1,100 | $91K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,178 | $90K |
| 82728 | <1% | 6,283 | $90K | |
| 43248 | <1% | 419 | $90K | |
| 94762 | <1% | 3,310 | $89K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,140 | $87K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 17,202 | $86K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 517 | $85K |
| 84702 | <1% | 4,100 | $85K | |
| 86850 | <1% | 5,192 | $84K | |
| 80076 | <1% | 19,209 | $83K | |
| 73562 | <1% | 3,215 | $83K | |
| 73610 | <1% | 3,123 | $82K | |
| 74183 | <1% | 351 | $80K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 55,795 | $79K |
| 80081 | <1% | 2,930 | $77K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 118 | $76K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,018 | $76K |
| 72110 | <1% | 1,722 | $73K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,819 | $73K |
| 86780 | <1% | 3,163 | $72K | |
| 86703 | <1% | 3,346 | $72K | |
| 73130 | <1% | 3,082 | $72K | |
| 72100 | <1% | 1,998 | $71K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 409 | $70K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,181 | $69K |
| 73030 | <1% | 2,808 | $66K | |
| 81001 | <1% | 58,974 | $65K | |
| 20553 | <1% | 473 | $64K | |
| 76770 | <1% | 458 | $64K | |
| 97165 | <1% | 963 | $64K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 558 | $63K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 553 | $62K |
| 12011 | <1% | 405 | $61K | |
| 86900 | <1% | 5,411 | $59K | |
| 64493 | <1% | 217 | $59K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 609 | $59K |
| 10060 | <1% | 420 | $59K | |
| 80074 | <1% | 3,212 | $59K | |
| 87070 | <1% | 4,711 | $58K | |
| 95885 | <1% | 245 | $57K | |
| 97035 | <1% | 1,074 | $57K | |
| 43249 | <1% | 185 | $56K | |
| 93925 | <1% | 543 | $56K | |
| 86803 | <1% | 3,024 | $56K | |
| 83735 | <1% | 26,465 | $54K | |
| 80069 | <1% | 4,917 | $54K | |
| 73110 | <1% | 2,085 | $54K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 1,189 | $52K |
| 71045 | Radiologic examination, chest; single view | <1% | 30,426 | $52K |
| 70544 | <1% | 282 | $51K | |
| 92557 | <1% | 490 | $51K | |
| 75574 | <1% | 146 | $49K | |
| 93880 | <1% | 763 | $48K | |
| 95806 | <1% | 212 | $48K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,208 | $47K |
| 27096 | <1% | 198 | $46K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 507 | $46K |
| 97116 | <1% | 1,639 | $46K | |
| 93922 | <1% | 710 | $46K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,475 | $45K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 628 | $45K |
| 86140 | <1% | 6,833 | $45K | |
| 82565 | <1% | 6,972 | $44K | |
| 87077 | <1% | 4,745 | $44K | |
| 52260 | <1% | 46 | $43K | |
| 84153 | <1% | 2,604 | $43K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,356 | $42K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,365 | $41K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 679 | $41K |
| 72050 | <1% | 720 | $41K | |
| 70486 | <1% | 896 | $41K | |
| 82570 | <1% | 5,907 | $41K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 19,582 | $40K |
| 72072 | <1% | 1,034 | $39K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 985 | $39K |
| 87186 | <1% | 5,953 | $38K | |
| 76801 | <1% | 723 | $38K | |
| 29848 | <1% | 26 | $38K | |
| 72131 | <1% | 611 | $38K | |
| 76882 | <1% | 375 | $38K | |
| 95911 | <1% | 352 | $37K | |
| 72040 | <1% | 809 | $37K | |
| 86038 | <1% | 2,310 | $37K | |
| 73502 | <1% | 1,448 | $36K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,677 | $35K |
| 82746 | <1% | 3,032 | $35K | |
| 83970 | <1% | 1,503 | $35K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 3,781 | $35K |
| 12002 | <1% | 253 | $34K | |
| 97113 | <1% | 501 | $34K | |
| 77336 | <1% | 461 | $34K | |
| C1776 | Joint device (implantable) | <1% | 128 | $34K |
| 70498 | <1% | 915 | $34K | |
| 88112 | <1% | 888 | $33K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 82 | $33K |
| 87522 | Neg quan hep c or qual rna | <1% | 1,107 | $33K |
| 74174 | <1% | 291 | $32K | |
| 83540 | <1% | 4,242 | $32K | |
| 88341 | <1% | 765 | $32K | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | <1% | 803 | $31K |
| 52356 | <1% | 20 | $31K | |
| 87493 | <1% | 958 | $30K | |
| 84403 | <1% | 1,482 | $30K | |
| 84450 | <1% | 5,476 | $30K | |
| 93325 | <1% | 402 | $30K | |
| 87400 | <1% | 1,560 | $30K | |
| 86592 | <1% | 1,079 | $29K | |
| 85652 | <1% | 8,639 | $28K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 46,521 | $28K |
| 73120 | <1% | 852 | $28K | |
| 83605 | <1% | 14,410 | $28K | |
| 85610 | <1% | 7,705 | $28K | |
| 84460 | <1% | 5,812 | $28K | |
| 97598 | <1% | 125 | $27K | |
| 87081 | <1% | 2,175 | $27K | |
| 77080 | <1% | 382 | $27K | |
| 43235 | <1% | 115 | $27K | |
| 82043 | <1% | 4,531 | $26K | |
| 80320 | <1% | 2,789 | $26K | |
| 77334 | <1% | 182 | $26K | |
| 84146 | <1% | 1,376 | $26K | |
| 96523 | <1% | 677 | $26K | |
| 64483 | <1% | 55 | $25K | |
| 87340 | <1% | 1,657 | $25K | |
| 90837 | Psychotherapy session, about an hour | <1% | 269 | $25K |
| 74019 | <1% | 355 | $25K | |
| 90715 | <1% | 1,901 | $25K | |
| 73080 | <1% | 1,199 | $24K | |
| 88307 | <1% | 393 | $23K | |
| 47562 | <1% | 15 | $23K | |
| 83516 | <1% | 1,476 | $23K | |
| 84270 | <1% | 1,289 | $23K | |
| 86901 | <1% | 5,398 | $23K | |
| 86160 | <1% | 2,259 | $23K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,870 | $23K |
| 73140 | <1% | 740 | $22K | |
| 83001 | <1% | 981 | $22K | |
| 87902 | <1% | 156 | $22K | |
| 77065 | Tomosynthesis, mammo | <1% | 589 | $21K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 897 | $20K |
| 64415 | <1% | 143 | $20K | |
| 97166 | <1% | 259 | $20K | |
| 27447 | <1% | 13 | $19K | |
| 86480 | <1% | 644 | $19K | |
| 82962 | <1% | 17,003 | $18K | |
| 82784 | <1% | 1,514 | $18K | |
| 82533 | <1% | 733 | $18K | |
| 77386 | <1% | 91 | $18K | |
| 82105 | <1% | 917 | $17K | |
| 83550 | <1% | 3,156 | $17K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 814 | $17K |
| 73560 | <1% | 799 | $17K | |
| 73521 | <1% | 528 | $17K | |
| 82040 | <1% | 1,749 | $16K | |
| 86431 | <1% | 1,947 | $16K | |
| 82247 | <1% | 2,017 | $16K | |
| 64400 | <1% | 58 | $16K | |
| 73590 | <1% | 1,057 | $15K | |
| 86200 | <1% | 1,506 | $15K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 49 | $15K |
| 86235 | <1% | 1,407 | $15K | |
| 92567 | <1% | 863 | $15K | |
| 88342 | <1% | 1,472 | $15K | |
| 80349 | <1% | 768 | $15K | |
| 20552 | <1% | 119 | $15K | |
| 87046 | <1% | 1,785 | $14K | |
| 86706 | <1% | 1,194 | $14K | |
| 93312 | <1% | 63 | $14K | |
| 88738 | <1% | 2,069 | $14K | |
| 83690 | <1% | 30,322 | $14K | |
| 82805 | <1% | 590 | $14K | |
| 86618 | <1% | 887 | $14K | |
| 82950 | <1% | 1,493 | $14K | |
| 76870 | <1% | 429 | $14K | |
| 82248 | <1% | 2,047 | $13K | |
| 95909 | <1% | 276 | $13K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 489 | $13K |
| 83880 | <1% | 4,314 | $13K | |
| 86696 | <1% | 694 | $13K | |
| 71101 | <1% | 639 | $13K | |
| 78227 | <1% | 44 | $13K | |
| 20611 | <1% | 52 | $13K | |
| 94664 | <1% | 4,982 | $12K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 718 | $12K |
| 87045 | <1% | 923 | $12K | |
| 77066 | Tomosynthesis, mammo | <1% | 335 | $12K |
| 73090 | <1% | 856 | $12K | |
| 94618 | <1% | 179 | $12K | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 168 | $11K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 37,733 | $11K |
| 86376 | <1% | 638 | $11K | |
| 92523 | <1% | 168 | $11K | |
| 87205 | <1% | 5,304 | $11K | |
| 72052 | <1% | 232 | $11K | |
| 82550 | <1% | 2,265 | $10K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 280 | $10K |
| 96376 | <1% | 6,162 | $10K | |
| 86256 | <1% | 791 | $10K | |
| 93225 | <1% | 97 | $10K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 314 | $10K |
| 86704 | <1% | 596 | $10K | |
| 20610 | <1% | 107 | $10K | |
| 83002 | <1% | 655 | $10K | |
| 73700 | <1% | 88 | $10K | |
| 95913 | <1% | 232 | $10K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 163 | $9K |
| 84550 | <1% | 2,515 | $9K | |
| 73200 | <1% | 85 | $9K | |
| 77300 | <1% | 71 | $9K | |
| 83721 | <1% | 829 | $9K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,522 | $9K |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 297 | $9K |
| 84480 | <1% | 702 | $9K | |
| 80197 | <1% | 597 | $8K | |
| 86695 | <1% | 512 | $8K | |
| 0240U | <1% | 47 | $8K | |
| 93799 | <1% | 450 | $8K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 730 | $8K |
| 77295 | <1% | 14 | $8K | |
| 82627 | <1% | 287 | $8K | |
| 86920 | <1% | 355 | $8K | |
| 87147 | <1% | 1,499 | $8K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 191 | $7K |
| 73060 | <1% | 446 | $7K | |
| 87328 | <1% | 698 | $7K | |
| 74160 | <1% | 74 | $7K | |
| 83525 | <1% | 300 | $7K | |
| 80164 | <1% | 484 | $7K | |
| 84100 | <1% | 1,861 | $7K | |
| C1769 | Guide wire | <1% | 1,881 | $6K |
| 72128 | <1% | 206 | $6K | |
| 87329 | <1% | 707 | $6K | |
| 81025 | <1% | 35,354 | $6K | |
| 94660 | <1% | 47 | $6K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 16 | $6K |
| 84132 | <1% | 2,076 | $6K | |
| 81596 | <1% | 73 | $6K | |
| 80171 | <1% | 301 | $6K | |
| 84156 | <1% | 1,572 | $6K | |
| 73552 | <1% | 480 | $6K | |
| 82947 | <1% | 1,354 | $5K | |
| 82150 | <1% | 542 | $5K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 4,353 | $5K |
| 85018 | <1% | 1,878 | $5K | |
| 72082 | <1% | 64 | $5K | |
| 85014 | <1% | 1,425 | $5K | |
| 85379 | <1% | 3,939 | $5K | |
| 87088 | <1% | 706 | $5K | |
| 90686 | <1% | 400 | $5K | |
| 62321 | <1% | 15 | $4K | |
| 83520 | <1% | 219 | $4K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 305 | $4K |
| 86708 | <1% | 395 | $4K | |
| 72146 | <1% | 29 | $4K | |
| 87150 | <1% | 152 | $4K | |
| 93975 | <1% | 44 | $4K | |
| 83615 | <1% | 2,894 | $4K | |
| 82977 | <1% | 665 | $4K | |
| 77301 | <1% | 14 | $4K | |
| J8501 | Aprepitant, oral, 5 mg | <1% | 288 | $4K |
| 82677 | <1% | 96 | $4K | |
| 80177 | <1% | 281 | $4K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,032 | $4K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 11,590 | $4K |
| 82670 | <1% | 167 | $4K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,405 | $4K |
| 84144 | <1% | 166 | $4K | |
| 84703 | <1% | 382 | $4K | |
| 97760 | <1% | 52 | $3K | |
| 84520 | <1% | 1,200 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 52,535 | $3K |
| 86308 | <1% | 542 | $3K | |
| 95908 | <1% | 86 | $3K | |
| 88304 | <1% | 1,525 | $3K | |
| 72170 | <1% | 941 | $3K | |
| 82140 | <1% | 567 | $3K | |
| 72158 | <1% | 13 | $3K | |
| 82951 | <1% | 128 | $3K | |
| 86147 | <1% | 135 | $3K | |
| 84445 | <1% | 116 | $3K | |
| 86334 | <1% | 154 | $3K | |
| 80324 | <1% | 128 | $3K | |
| 97014 | <1% | 65 | $2K | |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | <1% | 49 | $2K |
| 64450 | <1% | 45 | $2K | |
| 80051 | <1% | 291 | $2K | |
| 86665 | <1% | 119 | $2K | |
| 72156 | <1% | 12 | $2K | |
| 84075 | <1% | 551 | $2K | |
| 85730 | <1% | 1,947 | $2K | |
| 84681 | <1% | 159 | $2K | |
| 87040 | <1% | 3,641 | $2K | |
| 84145 | <1% | 2,798 | $2K | |
| 94010 | <1% | 27 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 13,009 | $2K |
| 82330 | <1% | 687 | $2K | |
| 81002 | <1% | 11,489 | $2K | |
| 85045 | <1% | 535 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,163 | $2K |
| 86225 | <1% | 140 | $2K | |
| 77002 | <1% | 25 | $2K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 40 | $2K |
| 77470 | <1% | 15 | $2K | |
| 95910 | <1% | 74 | $1K | |
| 86694 | <1% | 120 | $1K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 158 | $1K |
| 64447 | <1% | 29 | $1K | |
| 86705 | <1% | 113 | $1K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 17 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 25,707 | $1K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 209 | $1K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,494 | $1K |
| 29125 | <1% | 545 | $1K | |
| T1002 | Rn services, up to 15 minutes | <1% | 54 | $1K |
| 85597 | <1% | 20 | $1K | |
| 88142 | <1% | 66 | $1K | |
| 86709 | <1% | 136 | $1K | |
| 80178 | <1% | 125 | $1K | |
| 86336 | <1% | 96 | $1K | |
| 86762 | <1% | 55 | $1K | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 899 | $1K |
| 97803 | <1% | 12 | $1K | |
| 80359 | <1% | 114 | $1K | |
| 86880 | <1% | 136 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 13,385 | $1K |
| 84155 | <1% | 470 | $1K | |
| 86800 | <1% | 89 | $1K | |
| 36600 | <1% | 683 | $1K | |
| 84425 | <1% | 113 | $1K | |
| 82310 | <1% | 205 | $987.18 | |
| 97164 | <1% | 13 | $981.14 | |
| 86870 | <1% | 34 | $927.14 | |
| 92579 | <1% | 13 | $922.64 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15,219 | $919.69 |
| 77338 | <1% | 12 | $918.74 | |
| 87210 | <1% | 767 | $908.31 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 1,921 | $907.23 |
| J3590 | Unclassified biologics | <1% | 101 | $901.71 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 338 | $874.82 |
| 85049 | <1% | 444 | $853.59 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 15,630 | $850.76 |
| 74022 | <1% | 37 | $836.27 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 34,977 | $828.03 |
| J3535 | Drug administered through a metered dose inhaler | <1% | 260 | $817.83 |
| 83883 | <1% | 150 | $777.89 | |
| 29130 | <1% | 138 | $756.16 | |
| 72220 | <1% | 13 | $751.36 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 13,328 | $742.44 |
| 88173 | <1% | 116 | $730.89 | |
| 82803 | <1% | 777 | $709.28 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 5,340 | $690.56 |
| 86003 | <1% | 36 | $690.46 | |
| 76942 | <1% | 79 | $684.18 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,633 | $680.25 |
| 36416 | <1% | 4,461 | $668.67 | |
| 70547 | <1% | 25 | $657.75 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,240 | $656.83 |
| 85598 | <1% | 20 | $656.10 | |
| 96402 | <1% | 112 | $655.71 | |
| 00910 | <1% | 62 | $649.68 | |
| 96417 | <1% | 1,394 | $619.99 | |
| 80329 | <1% | 459 | $612.86 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 28,856 | $611.50 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,566 | $604.24 |
| 00731 | <1% | 642 | $587.53 | |
| 00840 | <1% | 226 | $586.38 | |
| 00400 | <1% | 189 | $585.25 | |
| 82024 | <1% | 16 | $560.88 | |
| 00790 | <1% | 375 | $553.97 | |
| 29515 | <1% | 148 | $546.61 | |
| 86787 | <1% | 20 | $545.39 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,015 | $479.58 |
| 81050 | <1% | 96 | $452.19 | |
| 73000 | <1% | 12 | $428.23 | |
| 77370 | <1% | 13 | $426.98 | |
| 71111 | <1% | 13 | $419.94 | |
| 83630 | <1% | 25 | $413.69 | |
| 82010 | <1% | 537 | $399.78 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,394 | $399.61 |
| 85635 | <1% | 20 | $388.39 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,028 | $384.09 |
| 92610 | <1% | 13 | $363.64 | |
| 82553 | <1% | 20 | $359.14 | |
| 96368 | <1% | 226 | $352.84 | |
| 82378 | <1% | 76 | $350.22 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,075 | $349.96 |
| 85007 | <1% | 79 | $349.00 | |
| 88360 | <1% | 15 | $337.48 | |
| 90656 | <1% | 79 | $333.91 | |
| 82575 | <1% | 17 | $331.49 | |
| 00160 | <1% | 51 | $321.69 | |
| J7605 | Arformoterol, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 15 micrograms | <1% | 883 | $320.01 |
| 99195 | <1% | 15 | $312.50 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 889 | $300.21 |
| 51798 | <1% | 84 | $267.77 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 389 | $264.65 |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | <1% | 208 | $260.47 |
| 84295 | <1% | 690 | $253.42 | |
| 73660 | <1% | 15 | $252.97 | |
| 80354 | <1% | 76 | $249.96 | |
| 84305 | <1% | 15 | $245.71 | |
| 83993 | <1% | 18 | $244.81 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 511 | $218.90 |
| 82103 | <1% | 16 | $207.53 | |
| 85732 | <1% | 40 | $204.22 | |
| 80361 | <1% | 17 | $202.54 | |
| 85613 | <1% | 47 | $196.22 | |
| 85670 | <1% | 20 | $187.34 | |
| 82164 | <1% | 14 | $181.26 | |
| 84436 | <1% | 27 | $178.19 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 970 | $177.17 |
| 84466 | <1% | 14 | $173.00 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 85 | $170.44 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 724 | $168.65 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,174 | $161.70 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,980 | $157.43 |
| 82435 | <1% | 632 | $157.06 | |
| 80365 | <1% | 13 | $151.03 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 146 | $150.96 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,504 | $143.55 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,077 | $141.50 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 418 | $131.65 |
| 82375 | <1% | 598 | $128.04 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 282 | $120.02 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 848 | $118.90 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 2,806 | $118.20 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 956 | $113.61 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,880 | $112.26 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 725 | $111.97 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 13,740 | $107.61 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 431 | $107.19 |
| 85705 | <1% | 20 | $102.11 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 4,872 | $97.60 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 776 | $88.10 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,221 | $82.42 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 653 | $80.13 |
| 93321 | <1% | 14 | $73.28 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,043 | $71.97 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,615 | $71.72 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 891 | $67.62 |
| 89051 | <1% | 18 | $57.33 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 994 | $56.95 |
| 83050 | <1% | 593 | $55.48 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 4,164 | $55.13 |
| 86146 | <1% | 20 | $50.70 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 112 | $48.92 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,111 | $48.76 |
| J7070 | Infusion, d5w, 1000 cc | <1% | 764 | $48.43 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 3,224 | $38.77 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 115 | $33.79 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 12 | $27.21 |
| J1335 | Injection, ertapenem sodium, 500 mg | <1% | 24 | $25.94 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 26 | $22.99 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 61 | $21.56 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 616 | $20.31 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 209 | $19.29 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 2,030 | $18.64 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 473 | $16.84 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 178 | $15.96 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 15 | $15.57 |
| 85347 | <1% | 85 | $15.42 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 36 | $14.77 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 1,080 | $12.62 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 417 | $11.52 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 874 | $9.35 |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 184 | $7.56 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 49 | $4.82 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 161 | $2.33 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 31 | $2.22 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 230 | $1.71 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 40 | $1.53 |
| J1805 | Injection, esmolol hydrochloride, 10 mg | <1% | 14 | $1.34 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 17 | $0.90 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 32 | $0.29 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 149 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 3,532 | $0.00 |
| 01830 | 0% | 99 | $0.00 | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 683 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 565 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 133 | $0.00 |
| 01810 | 0% | 368 | $0.00 | |
| 00811 | 0% | 112 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 2,328 | $0.00 |
| 82800 | 0% | 83 | $0.00 | |
| 76376 | 0% | 732 | $0.00 | |
| 00918 | 0% | 21 | $0.00 | |
| 20930 | 0% | 14 | $0.00 | |
| 95912 | 0% | 17 | $0.00 | |
| J2720 | Injection, protamine sulfate, per 10 mg | 0% | 12 | $0.00 |
| 51702 | 0% | 26 | $0.00 | |
| 96549 | 0% | 181 | $0.00 | |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 19 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 26 | $0.00 |
| 22853 | 0% | 26 | $0.00 | |
| 00300 | 0% | 57 | $0.00 | |
| 01402 | 0% | 14 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 713 | $0.00 |
| A9270 | Non-covered item or service | 0% | 2,000 | $0.00 |
| 96411 | 0% | 482 | $0.00 | |
| 00813 | 0% | 558 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 100 | $0.00 |
| 88311 | 0% | 17 | $0.00 | |
| J0173 | Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg | 0% | 44 | $0.00 |
| C1888 | Catheter, ablation, non-cardiac, endovascular (implantable) | 0% | 183 | $0.00 |
| 01480 | 0% | 73 | $0.00 | |
| 93320 | 0% | 328 | $0.00 | |
| 77001 | 0% | 27 | $0.00 | |
| 00126 | 0% | 59 | $0.00 | |
| 64494 | 0% | 133 | $0.00 | |
| 00952 | 0% | 12 | $0.00 | |
| J9267 | Injection, paclitaxel, 1 mg | 0% | 25 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 18 | $0.00 |
| 01400 | 0% | 14 | $0.00 | |
| 95940 | 0% | 15 | $0.00 | |
| C1778 | Lead, neurostimulator (implantable) | 0% | 30 | $0.00 |
| 95938 | 0% | 15 | $0.00 | |
| 94761 | 0% | 23 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNORMAN, MICHAEL (CSO)
| Provider | Location | Paid |
|---|---|---|
| Genesis Emergency Physicians LLC | Zanesville, OH | $10.78M |
| Genesis Primary Care Physicians LLC | Zanesville, OH | $7.08M |
| Genesis Healthcare System | Zanesville, OH | $4.27M |
| Community Ambulance Service | Zanesville, OH | $3.75M |
| Professionals PRN LLC | Zanesville, OH | $3.21M |
| Elm Family Dental Associates LLC | West Haven, CT | $1.26M |
| Genesis Anesthesia Providers, LLC | Zanesville, OH | $288K |
| Genesis Healthcare System | Zanesville, OH | $4K |
| Genesis Healthcare System | Zanesville, OH | $582.68 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.